Skip to search formSkip to main contentSkip to account menu
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
TLDR
An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
View on PubMed
Genomic aberrations and survival in chronic lymphocytic leukemia.
TLDR
Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
View on PubMed
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
TLDR
An international expert panel is provided to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials.
View on PubMed
Genomic Classification and Prognosis in Acute Myeloid Leukemia.
TLDR
The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification.
View on PubMed
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
TLDR
Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.
View on PubMed
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
TLDR
The addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall and event‐free survival among patients with AML and a FLT3 mutation.
View on Wolters Kluwer
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
TLDR
Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
View on PubMed
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
TLDR
NPM1 mutations in the absence of FLT3 ITD define a distinct molecular and prognostic subclass of young-adult AML patients with normal cytogenetics, and is associated with specific clinical, phenotypical, and genetic features.
View on PubMed
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3…
TLDR
IDH1 and IDH2 mutations are recurring genetic changes in AML that constitute a poor prognostic factor in CN-AML with mutated NPM1 without FLT3-ITD, which allows refined risk stratification of this AML subset.
View on PubMed
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
TLDR
ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License